gip glp 1 agonist tirzepatide Frontiers Effects of tirzepatide, a dual

After the success of these first-generation GLP-1 medications in T2D, scientists continued to discover the wide-reaching effects and applications of this remarkable hormone

Notably, the SOS study showed that in people with T2D, achieving and maintaining 15% WL over 15 years was associated with reductions in both micro- and macrovascular complications following BS [54]

Saxenda (Liraglutide) FDA approval: 2014 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Also available as: Victoza (lower dose, approved for Type 2 diabetes) Ozempic (Semaglutide) FDA approval: 2017 for Type 2 diabetes Indicated population: Adults with Type 2 diabetes as adjunct to diet and exercise Not approved for: Weight loss (though commonly prescribed off-label) Wegovy (Semaglutide) FDA approval: 2021 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Adolescents aged 12+ with obesity Same medication as Ozempic: Different dosing and FDA indication Practical Implications The regulatory distinctions matter for: Insurance coverage: Medications are often covered only for their approved indications

24 however, we are not aware of any other guidance on switching between GLP1RAs

doi: 10.2337/dc19-1892